Skip to Content

Emgality vs Aimovig - how do they compare?

Medically reviewed by Melisa Puckey, BPharm. Last updated on Aug 26, 2020.

Official Answer

by Drugs.com

How does the effectiveness of Emgality and Aimovig compare?

In clinical trials that studied how well Emgality (galcanezumab) and Aimovig (erenumab) worked to prevent chronic migraines showed:

  • Aimovig had a bigger decrease (-2.5 days) in migraine days per month compared to Emgality (-2.1 days).
  • Aimovig had a bigger percentage (16.4%) of patients who had their migraines reduced by half compared to Emgality (13%).

Emgality is also indicated to treat episodic cluster headaches in adults. Aimovig does not have an FDA approved indication to treat episodic cluster headaches.

How do the side effects of Emgality and Aimovig compare?

  • Aimovig has a rate of 6% for injection site reactions which is lower than Emgality injection site reactions of 18%.
  • Both Aimovig and Emgality have constipation and itchy skin as side effects which affects between 1 and 10% patients.
  • Aimovig has other common side effects including tiredness, cramps and muscle spasms.
  • Emgality has other common side effects including anti-drug-antibodies (up to 12.5%), dizziness and welts.
Aimovig (erenumab) Emgality (galcanezumab)
Indications for use Preventive treatment of migraine in adults Preventive treatment of migraine in adults
Treatment of episodic cluster headache in adults
FDA approval date 17 May 2018 - Preventive Treatment for Migraine 27 September 2018 - Preventive Treatment of Migraine in Adults
4 June 2019 - Treatment of episodic cluster headache
Form Subcutaneous injection Subcutaneous injection
Dose

Preventative migraine treatment: 70mg injected subcutaneously once monthly.
Some patients may benefit from a dosage of 140mg once a month.

Preventative migraine treatment: initially 240mg, then monthly 120mg subcutaneously
Episodic cluster headache treatment: 300 mg (3x100mg injections) at start of cluster period and then monthly until end of cluster period
Half life 28 days 27 days
Effectiveness Preventing Chronic Migraine:
Decrease in monthly migraine headache days
-2.5 days per month (Aimovig 70mg, Study 3)
-2.5 days per month (Aimovig 140mg, Study 3)
-2.1 days per month (Emgality 240mg loading dose, then 120mg monthly, Study 3)
Effectiveness Preventing Chronic Migraine:
Percentage of patients who had their migraines reduced by half.
16.4% (Aimovig 70mg, Study 3)
17.7% (Aimovig 140mg, Study 3)
13% (Emgality 240mg loading dose, then 120mg monthly, Study 3)
Effectiveness for Episodic Migraine: Decrease in days of migraine headache days per month -1.0 day per month (Aimovig 70mg, Study 2) -1.9 days per month (Emgality 240mg loading dose, then 120mg monthly, Study 1)
Effectiveness for Episodic Migraine: Decrease in number of days of acute migraine medicine taken per month -0.6 of a day per month (Aimovig 70mg, Study 2) -1.8 days per month (Emgality 240mg loading dose, then 120mg monthly, Study 1)
Side effects Injection site reactions 6%, constipation, itchy skin, tiredness, cramps and muscle spasms. Injection site reactions 18%, anti-drug-antibodies (up to 12.5%), constipation, itchy skin, dizziness and welts.

Bottom line:

  • Aimovig had a slightly bigger decrease in chronic migraine days per month and also a bigger percentage of patients had their chronic migraines reduced by half compared to Emgality.
  • Emgality has more injections site reaction (18%) compared to Aimovig (6%), and both Emgality and Aimovig have a range of other side effects.
References

Related Medical Questions

Drug Information

Related Support Groups